JSPR Jasper Therapeutics, Inc. - Class A Common Stock
$0.83
Price · May 20, 2026
Fundamentals as of May 14, 2026
52W Range
$1–$7
3% of range
Analyst Rating
BUY
14 analysts
Price Target
$8
+803% upside
P/E (TTM)
-0.5
ROE
—
Net Profit Margin
—
JSPR Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$0.83
Market Cap
—
P/E (TTM)
-0.5
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$1 – $7
JSPR Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
JSPR
Peer Median
P/E (TTM)
-0.5
—
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
JSPR
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
JSPR
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
JSPR
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
JSPR
Peer Median
JSPR Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
14 analysts
- Strong Buy 3 21.4%
- Buy 7 50.0%
- Hold 4 28.6%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
5 analysts · 2026-05-17
Median
$6.00
Mean
$7.50
← Below all targets
$0.83
Low
$1.50
High
$20.00
Median target
$6.00
+622.5%
Mean target
$7.50
+803.2%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
0.01%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| March 31, 2026 | $-0.04 | $-0.50 | 0.46% |
| Dec. 31, 2025 | $-0.32 | $-0.76 | 0.44% |
| Sept. 30, 2025 | $-1.25 | $-1.24 | -0.01% |
| June 30, 2025 | $-1.74 | $-1.35 | -0.39% |
| March 31, 2025 | $-1.41 | $-1.34 | -0.07% |
| Dec. 31, 2024 | $-1.62 | $-1.25 | -0.36% |
Peer Comparison Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| JSPR | — | -0.5 | — | — | — | — |
| AIXC | $12M | -0.3 | — | — | -110.8% | — |
| VTGN | — | -1.5 | -54.3% | -10579.8% | -67.9% | — |
| CLRB | — | -0.4 | — | — | — | — |
| KTTA | — | — | — | — | — | — |
| SNSE | $13M | -0.6 | — | — | -91.9% | — |
| GRDX | $20M | -1.1 | — | -17634.4% | -68.6% | -1813.6% |
| CELU | $32M | -0.3 | -51.0% | -345.4% | 288.6% | — |
| MRKR | $25M | -1.9 | -46.2% | -343.0% | -89.1% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Balance Sheet 19
| Metric | Trend | 2025 |
|---|---|---|
| Cash & Equivalents | $29M | |
| Prepaid Expense | $6M | |
| Other Current Assets | $664.0K | |
| Current Assets | $35M | |
| PP&E (Net) | $102.0K | |
| PP&E (Gross) | $5M | |
| Accum. Depreciation | $5M | |
| Other Non-current Assets | $113.0K | |
| Total Assets | $36M | |
| Accounts Payable | $6M | |
| Current Liabilities | $13M | |
| Other Non-current Liabilities | $2M | |
| Total Liabilities | $32M | |
| Common Stock | $3.0K | |
| Paid-in Capital | $321M | |
| Retained Earnings | $-317M | |
| Stockholders' Equity | $4M | |
| Liabilities + Equity | $36M | |
| Shares Outstanding | 27,996,819 |
Valuation (TTM) 4
| Metric | Trend | 2025 |
|---|---|---|
| Revenue TTM | $-119.0K | |
| Net Income TTM | $-76M | |
| P/E | -0.5 | |
| Earnings Yield | -215.9% |
Income Statement 13
| Metric | Trend | Q1 2026 |
|---|---|---|
| Cost of Revenue | $4M | |
| R&D Expense | $6M | |
| SG&A Expense | $5M | |
| Operating Expenses | $11M | |
| Operating Income | $-11M | |
| Interest Income | $164.0K | |
| Other Non-op | $-26.0K | |
| Net Income | $-1M | |
| EPS (Basic) | $-0.04 | |
| EPS (Diluted) | $-0.04 | |
| Shares (Basic) | 28,671,819 | |
| Shares (Diluted) | 28,671,819 | |
| EBITDA | $-11M |
Balance Sheet 19
| Metric | Trend | Q1 2026 |
|---|---|---|
| Cash & Equivalents | $14M | |
| Prepaid Expense | $6M | |
| Other Current Assets | $405.0K | |
| Current Assets | $20M | |
| PP&E (Net) | $81.0K | |
| PP&E (Gross) | $5M | |
| Accum. Depreciation | $5M | |
| Other Non-current Assets | $77.0K | |
| Total Assets | $21M | |
| Accounts Payable | $2M | |
| Current Liabilities | $9M | |
| Other Non-current Liabilities | $2M | |
| Total Liabilities | $18M | |
| Common Stock | $3.0K | |
| Paid-in Capital | $321M | |
| Retained Earnings | $-318M | |
| Stockholders' Equity | $3M | |
| Liabilities + Equity | $21M | |
| Shares Outstanding | 27,996,819 |
Cash Flow 5
| Metric | Trend | Q1 2026 |
|---|---|---|
| D&A | $21.0K | |
| Stock-based Comp | $423.0K | |
| Operating Cash Flow | $-15M | |
| Stock Issued | $6M | |
| Net Stock Activity | $6M |
Profitability 2
| Metric | Trend | Q1 2026 |
|---|---|---|
| ROA | -3.0% | |
| ROE | -5.1% |
Liquidity & Solvency 2
| Metric | Trend | Q1 2026 |
|---|---|---|
| Current Ratio | 2.3 | |
| Quick Ratio | 1.6 |
Valuation (TTM) 9
| Metric | Trend | Q1 2026 |
|---|---|---|
| Revenue TTM | $-119.0K | |
| Net Income TTM | $-68M | |
| Market Cap | $25M | |
| P/E | -0.2 | |
| P/S | -206.1 | |
| P/B | 7.2 | |
| P / Tangible Book | 7.2 | |
| P / Cash Flow | -1.7 | |
| Earnings Yield | -493.1% |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.